Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD known ✓ | O00329 | 1/20 | 0.43 |
| ▸ | HTR6 known ✓ | P50406 | 5/20 | 0.43 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.41 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.40 |
| ▸ | NMT1 | P30419 | 10/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | NMT2 | O60551 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15061210 | 0.99 | NMT1 (0.51) | NMT1PIK3CDPIK3CBMTORPIK3CG | |
| Hydrochloric Acid SCHEMBL4690124 | 0.84 | KDM2B (0.48) | PIK3CDPIK3CBMTORPIK3CGHTR6 | |
| SCHEMBL15061278 | 0.83 | KDM2B (0.48) | PIK3CDPIK3CBMTORPIK3CGHTR6 | |
| Hydrochloric Acid SCHEMBL4690120 | 0.82 | DRD2 (0.43) | NMT1PIK3CDPIK3CBMTORPIK3CG | |
| SCHEMBL15061277 | 0.81 | DRD2 (0.44) | NMT1PIK3CDPIK3CBMTORPIK3CG | |
| SCHEMBL4686763 | 0.81 | KMT2A (0.60) | NMT1HTR6MEN1GAAKMT2A | |
| SCHEMBL4687564 | 0.76 | HTR6 (0.46) | HTR6KMT2AKCNH2 | |
| Hydrochloric Acid SCHEMBL3609692 | 0.74 | HTR6 (0.51) | HTR6KCNH2 | |
| SCHEMBL13552985 | 0.73 | HTR6 (0.47) | NMT1HTR6NMT2KCNH2 | |
| SCHEMBL3609962 | 0.73 | HTR6 (0.52) | HTR6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476275-B2 | N-[piperazinyl hetaryl]arylsufonamide compounds with affinity for the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-07-02 | — | — | US | disclosed |
| US-20110294817-A1 | N-[PIPERAZINYL HETARYL]ARYLSUFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2011-12-01 | — | — | US | disclosed |
| EP-1613596-B1 | N-[(PIPERAZINYL)HETARYL]ARYLSULFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2008-03-12 | — | — | EP | disclosed |
| US-7320979-B2 | N-[(piperazinyl)hetaryl]arylsulfonamide compounds | ABBOTT GMBH & CO. KG. (DE) | 2008-01-22 | — | — | US | disclosed |
| US-20070054918-A1 | N-[(piperazinyl)hetary]arylsulfonamide compounds with affinity for the dopamine d3 receptor | ABBOTT GMBH & CO. KG (DE) | 2007-03-08 | — | — | US | disclosed |
| US-20060160809-A1 | N-[(piperazinyl)hetaryl]arylsulfonamide compounds | ABBOTT GMBH & CO. KG. | 2006-07-20 | — | — | US | disclosed |
| US-20040204422-A1 | N-[(Piperazinyl)hetaryl]arylsulfonamide compounds | ABBOTT GMBH & CO. KG. | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204422-A1 | N-[(Piperazinyl)hetaryl]arylsulfonamide compounds | CBR1, CBR3, CNR2 | PIK3CD 1518/4885HTR6 164/4885GAA 1351/4885 |
| US-20110294817-A1 | N-[PIPERAZINYL HETARYL]ARYLSUFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR | DRD2, DRD3, TACR1 | PIK3CD 1157/4885HTR6 151/4885GAA 3322/4885 |
| US-20070054918-A1 | N-[(piperazinyl)hetary]arylsulfonamide compounds with affinity for the dopamine d3 receptor | PTGDR, TACR1, TACR2 | PIK3CD 1332/4885HTR6 105/4885GAA 3515/4885 |
| US-20060160809-A1 | N-[(piperazinyl)hetaryl]arylsulfonamide compounds | CBR3, CNR2, CNR1 | PIK3CD 1329/4885HTR6 171/4885GAA 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.